PolTREG launches Phase 2 cell therapy trial in children with presymptomatic diabetes
24. Oktober 2024 01:00 ET
|
PolTREG S.A.
Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years’ worth of safety...
PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
26. September 2024 01:00 ET
|
PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
16. September 2024 01:00 ET
|
PolTREG S.A.
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
09. September 2024 01:00 ET
|
PolTREG S.A.
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
24. Juni 2024 01:30 ET
|
PolTREG S.A.
PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to...
PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab
04. April 2024 01:00 ET
|
PolTREG S.A.
New biomarker may facilitate monitoring T1D patients’ healthIncrease in PD-1+ T-cells correlated with therapeutic response and less insulin use Gdańsk, Poland – 4 April 2024 – PolTREG S.A. (Warsaw...
PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland
11. März 2024 02:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 11 March 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it...
PolTREG appoints Dan Shelly as Chief Business Development Officer
21. Februar 2024 01:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 21 February 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy
30. Januar 2024 01:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 30 January 2024 – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cell therapies for a wide range of autoimmune...
PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes
16. Januar 2024 01:00 ET
|
PolTREG S.A.
Gdańsk, Poland – 16 January 2024, 07:00 CET – PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide...